In conclusion, antibodies against ErbB3 may become new tools in our repertoire of anticancer agents for the therapy of NSCLC because of their ability to potentiate the effect of EGFR inhibitors. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.